Literature DB >> 11468321

Labeling of rat neurons by anti-GluR3 IgG from patients with Rasmussen encephalitis.

C Frassoni1, R Spreafico, S Franceschetti, N Aurisano, P Bernasconi, R Garbelli, C Antozzi, S Taverna, T Granata, R Mantegazza.   

Abstract

The authors report the immunocytochemical localization in rat brain of affinity-purified anti-GluR3 (glutamate receptor) antibodies from two patients with Rasmussen encephalitis (RE) and from immunized rabbits. The distribution of immunolabeling was similar using antibodies from rabbits and patients with RE. No electrophysiologic responses were elicited from acutely dissociated kainate-responsive neurons isolated from rat brain when these antibodies were applied. These findings show that anti-GluR3 antibodies purified from patients with RE bind to specific regions of the CNS but do not act through an excitotoxic mechanism.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11468321     DOI： 10.1212/wnl.57.2.324

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  [Recent insights into Rasmussen encephalitis].

Authors:  C G Bien; C E Elger
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

Review 2.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

3.  Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment.

Authors:  Maria Chiara Buscarinu; Arianna Fornasiero; Giulia Pellicciari; Roberta Reniè; Anna Chiara Landi; Alessandro Bozzao; Cristina Cappelletti; Pia Bernasconi; Giovanni Ristori; Marco Salvetti
Journal:  Brain Sci       Date:  2019-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.